Hamps Bio
- Market cap
- ₹ 22 Cr.
- P/E
- 72.6x
- P/B
- 2.69x
- 52-week range
- 13.36 – 26.58
- ROE
- −8%
- ROCE
- −2.8%
- Dividend yield
- 0%
- Debt / equity
- 0.85
- Sector
- Agricultural Food & other Products
- Industry
- Other Agricultural Products
- Listed on
- BSE SME
About
Hamps Bio Limited is an India-based company, which is engaged in pharmaceutical formulation and freeze-drying ingredient manufacturing and distributing. Its products include home pharmaceutical products and freeze-drying food products. Its home pharmaceutical products include antibiotic/antibacterial/antifungal; hematantic/calcium supplement; painkiller/ anti-inflammatory; antiacid/PPI; mouth wash; toothpaste; pediatric care; nutrition supplement, and injections. Its freeze-drying food products include ingredients for fruit tea / traditional tea; ingredients for fruit snacks / juice powder/ smoothie mix / ice cream; ingredients for noodles / instant food / ready to eat; ingredients for super food, and application like camel milk / curd / panner/ cheese / cow colostrum. Its injection products include ALLSEF; Beep 40; BMXCLAV; PTSEFT; SEFTZONE-1.5GM, and others. Its ingredients for super food include prickly pear, beet, spinach, noni, garcinia cambochia, and more.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Other Agricultural Products: 90 companies →Hamps Bio against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)72.6 against a typical 14.5: pricier than most peers (1st = cheapest).77th of 88
- Sales growth+36% against a typical +19.1% from a year earlier.22nd of 68
- Profit growth−300% against a typical +5.4% from a year earlier.57th of 59
- Share price, 3 months0% against a typical −1.7%.35th of 81
- Size₹ 21.8 Cr. market value against a typical ₹ 63 Cr. (1st = largest).64th of 85
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 3 | 4 | 3 | 4 | 5 |
| Expenses | 3 | 3 | 3 | 4 | 5 |
| Operating Profit | 1 | 1 | 0 | 0 | −0 |
| OPM % | 16.5% | 15.5% | 7% | 4.5% | −1.6% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 0 | 0 | 0 | −0 | −0 |
| Tax % | 25.8% | 25% | 25% | 0% | 7.1% |
| Net Profit | 0 | 0 | 0 | −0 | −0 |
| EPS in Rs | 0.59 | 0.43 | 0.03 | −0.23 | −0.53 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 15%
- TTM
- 28%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −317%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 3%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Hamps Bio | ₹ 25.50 | ₹ 22 Cr. | 72.6x | 2.7x | −8% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 26.2x | 2.5x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 67x | 13.2x | — | 21% |
| Pfizer | ₹ 3,610.00 | ₹ 16,511 Cr. | 23x | 4.2x | — | 28.6% |
| Unichem Laboratories | ₹ 472.00 | ₹ 3,294 Cr. | 46.5x | 1.3x | — | 13.2% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 33.3x | 5.3x | — | 15.5% |
Management
- Herrik Mountbaton Shah
- Managing Director, Executive Chairman of the Board
- Mitali Shah
- Chief Financial Officer
- Ravi Baheti
- Compliance Officer, Company Secretary
- Shrenikkumar Mountbaton Shah
- Whole Time Director
- Jyoti Chauhan
- Quality Control Head
- Purvaxy Dilkhush
- Food Sales Manager
- Prashant Gohel
- Production Manager
- Mansi Patel
- HR Admin
Prices are delayed and for information only. Nothing on this page is investment advice.